<DOC>
	<DOC>NCT03006055</DOC>
	<brief_summary>The GILUPI CellCollector® is the first in vivo CTC isolation product worldwide which is CE approved. Application data of CellCollector in China is not available now. The purpose of this clinical trial is to confirm the validation and safety of CellCollector in Chinese patients.</brief_summary>
	<brief_title>The Detection of Circulating Tumor Cells (CTCs) in Breast Cancer With a Novel in Vivo Device</brief_title>
	<detailed_description />
	<mesh_term>Neoplastic Cells, Circulating</mesh_term>
	<criteria>Metastasis breast cancer confirmed with imaging examination Have agreed to undergo CTC analysis in vivo; ECOG：02 Nonmetastasis breast cancer</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>